Neumora Therapeutics appoints new CEO and executive team

WATERTOWN, Mass. - Neumora Therapeutics , Inc. (NASDAQ:NMRA), a clinical-stage biopharmaceutical company focused on brain disease treatments, announced leadership changes effective February 14, with co-founder Paul L. Berns taking the helm as CEO and chairman of the Board. Henry Gosebruch is set to depart from the company. According to InvestingPro data, the company’s stock has seen significant pressure, down over 90% in the past year, though analysts see substantial upside potential with price targets ranging from $4 to $30.

The reshuffle also sees Joshua Pinto, Ph.D., stepping in as president, Bill Aurora, Pharm.D., as chief operating and development officer, and Michael Milligan as chief financial officer. Neumora, known for its innovative approach to neuroscience drug development, is working on seven clinical and pre-clinical programs targeting various brain diseases. InvestingPro analysis shows the company maintains a strong liquidity position with a current ratio of 10.98, though it’s currently burning through cash - a common characteristic for clinical-stage biotech companies.

Berns expressed confidence in the company’s pipeline and its potential to transform treatment for brain diseases. He highlighted the upcoming clinical data readouts from three programs in 2025, including a Phase 3 study on navacaprant for depression. With a market capitalization of $275 million and trading near its 52-week low, detailed analysis available through InvestingPro’s comprehensive research reports suggests the stock may be undervalued relative to its potential.

Dr. Pinto shared his enthusiasm for Neumora’s strong position in advancing studies for prevalent brain diseases and the near-term clinical inflection points expected.

Neumora will discuss its fourth quarter and full year 2024 financial results and provide a business update during a conference call on March 3, 2025. Participants can register for the call, which will also be webcast on the company’s website.

This press release contains forward-looking statements regarding Neumora’s mission, pipeline potential, leadership changes, financial position, and clinical development timelines. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected.

The information in this article is based on a press release statement from Neumora Therapeutics, Inc.

In other recent news, Neumora Therapeutics experienced a significant setback with the failure of its Phase 3 KOASTAL-1 trial for the drug navacaprant, intended to treat major depressive disorder (MDD). Despite the disappointing results, BofA Securities maintains a Buy rating on Neumora stock, albeit with a reduced price target, citing potential positive outcomes from the remaining trials, KOSTAL-2 and KOSTAL-3. Similarly, H.C. Wainwright and Mizuho (NYSE:MFG) Securities reiterated their Buy and Outperform ratings respectively, emphasizing the promising results among female patients and the possibility of success in the ongoing trials. In contrast, RBC Capital Markets downgraded Neumora stock to a Sector Perform rating following the trial failure, suggesting a more cautious approach until the company recovers. Neumora’s commitment to advancing novel therapies for improved treatment outcomes remains, with seven clinical and preclinical neuroscience programs in its pipeline.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.